Practices offered trial of new weekly oral NSAID Daxocox - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now


Practices offered trial of new weekly oral NSAID Daxocox

Animalcare is offering practice the chance to trial their new NSAID, Daxocox, by claiming £250 worth of the product free of charge

Animalcare is offering practices the opportunity to trial their new weekly NSAID for the management of osteoarthritis (OA) pain, Daxocox, by claiming £250 worth of the product completely free of charge. This is enough to treat six Springer Spaniels for four weeks.

To claim their free product, practices can simply sign up and use the stock selector to collate a product package that suits the patients they feel Daxocox could help.

Launched in 2021, Daxocox is a breakthrough in canine OA treatment, proven to effectively treat the pain and inflammation of OA in dogs with simple and convenient once weekly oral dosing. This is thanks to its unique seven-day phasic pharmacology which maintains consistent plasma levels between doses. Daxocox is licensed for all stages of canine OA, so can be used in any case where NSAIDs are not contraindicated.

Animalcare Marketing Manager James Beaumont explained: “When you consider that recent data shows that up to 20 percent of dogs over one year of age could have some form of OA, the scale of problem becomes clear – as does the threat to the welfare of our canine companions from OA pain.”

“Owners already giving Daxocox to their OA-affected pets have seen first-hand how it can significantly improve their quality of life. Ninety percent said that their dog’s osteoarthritis improved, with 84 percent reporting that their dog’s quality of life improved from ‘poor or fair’ to “good, very good or excellent.” (According to an internal report that is still pending publication).

He continued: “In a study carried out by Animalare, 88 percent of owners said that weekly NSAID dosing would be easier to remember or mean they were less likely to miss a dose or that it would control their dog’s pain more effectively.”

“Used as a first line treatment for OA, Daxocox can provide a solid foundation to long-term pain management that suits vets, dogs and their owners. As such, we’re confident that once practices have tried it, it will become their canine OA NSAID of choice.”

To find out more about Daxocox and how it works, visit the Daxocox website.

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more